X4 PHARMACEUTICALS, INC Financing Cash Flow
X4 PHARMACEUTICALS, INC (XFOR) reported Financing Cash Flow of $77.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $75.00K, a 98.67% decline year-over-year.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $2.00K.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $146.09M, a 108116.30% increase year-over-year.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $86.91M.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) financing activities for fiscal 2025 was $238.63M, a 1075.85% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) financing activities for fiscal 2024 was $20.29M, a 77.07% decline from fiscal 2023.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) financing activities for fiscal 2023 was $88.52M, a 24.49% decline from fiscal 2022.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) financing activities for fiscal 2022 was $117.23M, a 57.90% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $77.00K 10-Q · filed 2026-08-06 | $146.17M derived: sum of 3 quarters · filed 2026-08-06 | $233.07M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $2.00K 10-Q · filed 2026-05-06 | $146.09M derived: sum of 2 quarters · filed 2026-05-06 | $233.00M derived: sum of 3 quarters · filed 2026-05-06 | $238.63M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $146.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $233.00M derived: sum of 2 quarters · filed 2026-03-17 | $238.63M derived: sum of 3 quarters · filed 2026-08-06 | $238.63M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $86.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $92.54M derived: sum of 2 quarters · filed 2026-08-06 | $92.54M 10-Q · filed 2025-11-05 | $92.67M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $5.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.63M 10-Q · filed 2026-08-06 | $5.77M derived: sum of 3 quarters · filed 2026-08-06 | $5.77M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $135.00K derived: sum of 2 quarters · filed 2026-05-06 | $135.00K derived: sum of 3 quarters · filed 2026-05-06 | $20.29M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $135.00K derived: sum of 2 quarters · filed 2026-03-17 | $20.29M derived: sum of 3 quarters · filed 2026-03-17 | $20.29M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $20.16M derived: sum of 2 quarters · filed 2025-11-05 | $20.16M 10-Q · filed 2025-11-05 | $20.26M derived: sum of 4 quarters · filed 2026-03-17 | |||
| 2024-06-30 | $20.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $20.16M 10-Q · filed 2025-08-08 | $20.26M derived: sum of 3 quarters · filed 2026-03-17 | $41.46M derived: sum of 4 quarters · filed 2026-03-17 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $97.00K derived: sum of 2 quarters · filed 2026-03-17 | $21.30M derived: sum of 3 quarters · filed 2026-03-17 | $90.64M derived: sum of 4 quarters · filed 2026-03-17 | |||
| 2023-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $21.30M derived: sum of 2 quarters · filed 2026-03-17 | $90.64M derived: sum of 3 quarters · filed 2026-03-17 | $88.52M 10-K · filed 2026-03-17 | |||
| 2023-09-30 | $21.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $90.54M derived: sum of 2 quarters · filed 2024-11-13 | $88.42M 10-Q · filed 2024-11-13 | $149.06M derived: sum of 4 quarters · filed 2025-03-26 | |||
| 2023-06-30 | $69.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $67.21M 10-Q · filed 2024-08-08 | $127.86M derived: sum of 3 quarters · filed 2025-03-26 | $179.84M derived: sum of 4 quarters · filed 2025-03-26 | |||
| 2023-03-31 | -$2.12M 10-Q · filed 2024-05-07 | $58.52M derived: sum of 2 quarters · filed 2025-03-26 | $110.50M derived: sum of 3 quarters · filed 2025-03-26 | $110.15M derived: sum of 4 quarters · filed 2025-03-26 | |||
| 2022-12-31 | $60.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $112.62M derived: sum of 2 quarters · filed 2025-03-26 | $112.27M derived: sum of 3 quarters · filed 2025-03-26 | $117.23M 10-K · filed 2025-03-26 | |||
| 2022-09-30 | $51.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $51.63M derived: sum of 2 quarters · filed 2023-11-09 | $56.59M 10-Q · filed 2023-11-09 | $81.16M derived: sum of 4 quarters · filed 2024-03-21 | |||
| 2022-06-30 | -$347.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $4.61M 10-Q · filed 2023-08-10 | $29.18M derived: sum of 3 quarters · filed 2024-03-21 | $24.74M derived: sum of 4 quarters · filed 2024-03-21 | |||
| 2022-03-31 | $4.96M 10-Q · filed 2023-05-04 | $29.53M derived: sum of 2 quarters · filed 2024-03-21 | $25.08M derived: sum of 3 quarters · filed 2024-03-21 | $24.16M derived: sum of 4 quarters · filed 2024-03-21 | |||
| 2021-12-31 | $24.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $20.13M derived: sum of 2 quarters · filed 2024-03-21 | $19.20M derived: sum of 3 quarters · filed 2024-03-21 | $74.25M 10-K · filed 2024-03-21 | |||
| 2021-09-30 | -$4.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$5.37M derived: sum of 2 quarters · filed 2022-11-03 | $49.67M 10-Q · filed 2022-11-03 | $57.30M derived: sum of 4 quarters · filed 2023-03-21 | |||
| 2021-06-30 | -$924.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $54.12M 10-Q · filed 2022-08-04 | $61.75M derived: sum of 3 quarters · filed 2023-03-21 | $61.46M derived: sum of 4 quarters · filed 2023-03-21 | |||
| 2021-03-31 | $55.04M 10-Q · filed 2022-05-12 | $62.67M derived: sum of 2 quarters · filed 2023-03-21 | $62.39M derived: sum of 3 quarters · filed 2023-03-21 | $62.45M derived: sum of 4 quarters · filed 2023-03-21 | |||
| 2020-12-31 | $7.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $7.34M derived: sum of 2 quarters · filed 2023-03-21 | $7.41M derived: sum of 3 quarters · filed 2023-03-21 | $12.39M 10-K · filed 2023-03-21 | |||
| 2020-09-30 | -$284.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$219.00K derived: sum of 2 quarters · filed 2021-11-04 | $4.76M 10-Q · filed 2021-11-04 | $65.05M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2020-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $5.05M 10-Q · filed 2021-08-03 | $65.33M derived: sum of 3 quarters · filed 2022-03-17 | $58.92M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2020-03-31 | $4.98M 10-Q · filed 2021-05-06 | $65.27M derived: sum of 2 quarters · filed 2022-03-17 | $58.85M derived: sum of 3 quarters · filed 2022-03-17 | $145.53M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2019-12-31 | $60.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $53.87M derived: sum of 2 quarters · filed 2022-03-17 | $140.55M derived: sum of 3 quarters · filed 2022-03-17 | $140.66M 10-K · filed 2022-03-17 | |||
| 2019-09-30 | -$6.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $80.26M derived: sum of 2 quarters · filed 2020-11-05 | $80.38M 10-Q · filed 2020-11-05 | $85.41M derived: sum of 4 quarters · filed 2021-03-19 | |||
| 2019-06-30 | $86.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $86.79M 10-Q · filed 2020-08-04 | $91.82M derived: sum of 3 quarters · filed 2021-03-19 | $95.81M derived: sum of 4 quarters · filed 2021-03-19 | |||
| 2019-03-31 | $113.00K 10-Q · filed 2020-05-07 | $5.14M derived: sum of 2 quarters · filed 2021-03-19 | $9.14M derived: sum of 3 quarters · filed 2021-03-19 | $8.64M derived: sum of 4 quarters · filed 2021-03-19 | |||
| 2018-12-31 | $5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $9.02M derived: sum of 2 quarters · filed 2021-03-19 | $8.53M derived: sum of 3 quarters · filed 2021-03-19 | $6.87M 10-K · filed 2021-03-19 | -$4.53M 10-K · filed 2019-03-11 | ||
| 2018-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $3.50M derived: sum of 2 quarters · filed 2019-11-07 | $1.84M 10-Q · filed 2019-11-07 | -$1.64M 10-Q · filed 2018-11-09 | -$7.65M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | -$493.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$2.15M 10-Q · filed 2019-08-07 | -$1.06M 10-Q · filed 2018-08-13 | -$11.64M derived: sum of 3 quarters · filed 2020-03-12 | -$8.01M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | -$1.66M 10-Q · filed 2019-05-15 | -$11.15M derived: sum of 2 quarters · filed 2020-03-12 | -$7.51M derived: sum of 3 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | -$9.49M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$5.85M derived: sum of 2 quarters · filed 2020-03-12 | $33.42M 10-K · filed 2020-03-12 | $101.26M 10-K · filed 2019-03-11 | |||
| 2017-09-30 | $3.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $42.91M 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | $39.27M 10-Q · filed 2018-08-13 | ||||||
| 2016-12-31 | $18.15M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |